Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Tenax Therapeutics (TENX)

Tenax Therapeutics (TENX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,492
  • Shares Outstanding, K 25,207
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,850 K
  • 60-Month Beta 2.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.07
Trade TENX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.16
  • Number of Estimates 2
  • High Estimate -0.15
  • Low Estimate -0.17
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +73.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1100 +4.50%
on 12/06/21
1.5400 -24.68%
on 11/08/21
-0.4000 (-25.64%)
since 11/05/21
3-Month
1.1100 +4.50%
on 12/06/21
1.9594 -40.80%
on 10/04/21
-0.4100 (-26.11%)
since 09/03/21
52-Week
1.0100 +14.85%
on 12/21/20
3.6800 -68.48%
on 01/27/21
+0.0500 (+4.50%)
since 12/04/20

Most Recent Stories

More News
Tenax Therapeutics: Q3 Earnings Snapshot

MORRISVILLE, N.C. (AP) _ Tenax Therapeutics Inc. (TENX) on Tuesday reported a loss of $3.8 million in its third quarter.

TENX : 1.1600 (-0.85%)
Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high...

TENX : 1.1600 (-0.85%)
Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH)

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today...

TENX : 1.1600 (-0.85%)
Jobs Figures Due out Next Week Heading into Thanksgiving

Monday U.S. Economic Lookahead Factory Orders (Aug/) Featured Earnings Adamis Pharmaceuticals ...

ATZ.TO : 49.92 (+1.42%)
TENX : 1.1600 (-0.85%)
KTRA : 0.6000 (+4.64%)
PEP : 166.42 (+1.04%)
CMTL : 25.64 (+0.47%)
SAR : 28.97 (-0.10%)
STZ : 230.87 (+2.07%)
LEVI : 25.49 (+1.15%)
RPM : 95.43 (+2.04%)
AYI : 198.30 (+1.06%)
RGP : 17.15 (+0.82%)
HELE : 251.64 (+4.76%)
Tenax Therapeutics to Present at the Benzinga Healthcare Small Cap Conference

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today...

TENX : 1.1600 (-0.85%)
Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today...

TENX : 1.1600 (-0.85%)
Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high...

TENX : 1.1600 (-0.85%)
Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardiopulmonary diseases with a high unmet medical need, today...

TENX : 1.1600 (-0.85%)
Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high...

TENX : 1.1600 (-0.85%)
Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company that address cardiovascular and pulmonary diseases with high unmet medical need, today announced a CEO transition in connection...

TENX : 1.1600 (-0.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market. The Company specializes in creating pharmaceuticals and medical devices in the fields of oxygen therapeutics, blood substitutes, and liquid ventilation...

See More

Key Turning Points

3rd Resistance Point 1.2767
2nd Resistance Point 1.2333
1st Resistance Point 1.1967
Last Price 1.1600
1st Support Level 1.1167
2nd Support Level 1.0733
3rd Support Level 1.0367

See More

52-Week High 3.6800
Fibonacci 61.8% 2.6601
Fibonacci 50% 2.3450
Fibonacci 38.2% 2.0299
Last Price 1.1600
52-Week Low 1.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar